All trials - page: 66

All trials

Displaying of results
Download as CSV
NCTID
Brief title
Sponsor
Design
Criteria
Status
Target enrollment
Study phase & design
Primary intervention type
Primary potential benefit
Outcome measure
Follow up
Start date
First posted
Location
NCT02574572Autologous Mesenchymal Stem Cells Transplantation in Cervical Chronic and Complete Spinal Cord InjuryHospital Sao Rafael
  • Age 18 - 65 yrs
  • Level C5-C7
  • AIS A
  • ≥ 12 months
  • have a spinal cord injury for at least 12 months
  • have a neurological level of injury between C5 and C7
  • have the following ASIA impairment scale (AIS) grade:
  • AIS A: complete; no feeling or movement below the injury
  • be between 18 and 65 years of age
  • NOT have penetrating injury, e.g. gunshot or knife wound
  • NOT have other device implanted that would affect MRI, e.g. pacemaker
10PHASE1Biological/cell basedGeneral health
  • American Spinal Injury Association Impairment Scale (AIS): International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI)
12 months06 September 201714 October 20151
NCT02566850Investigational Study of the Ekso for High-Dosage Use by Individuals With SCI in a Non-Clinical EnvironmentEkso Bionics
  • Age 18 - 65 yrs
  • Level C1-S5
  • AIS A, B, C, D
  • All
  • have a body height between 152 and 193cm (5’-6’33 feet)
  • have a body weight of less than 100kg (<200 lbs)
  • have a prior experience or be willing to train on the Ekso device with a minimum of 20 hours and no more than 50 hours of device use and require no greater than minimal assist (support of up to 25% body weight) for safe and consistent walking. Participants with more than 50 hours of device experience must agree to a 1 month period of non-use prior to acquisition of baseline measures
Ended4NARehabilitationGeneral health
  • Adverse Events (AEs)
  • American Spinal Injury Association Impairment Scale (AIS): International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI)
  • Ashworth and Modified Ashworth Scale (MAS)
  • Bowel and bladder control
  • Spinal Cord Independence Measure (SCIM)
42 months01 January 201402 October 20151
NCT02564419Brain Machine Interface (BMI) in Subjects Living With QuadriplegiaUniversity of Miami
  • Age 22 - 50 yrs
  • Level C5-C6
  • AIS A, B
  • ≥ 6 months
Ended1NATechnologyArm/hand function
  • American Spinal Injury Association Impairment Scale (AIS): International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI)
  • Ashworth and Modified Ashworth Scale (MAS)
  • Short Form 36 (SF-36)
  • Spinal Cord Independence Measure (SCIM)
2 years01 November 201530 September 20151
NCT02524379Spinal Cord Injury Neuroprotection With GlyburideOhio State University
  • Age 18 - 80 yrs
  • Level C2-C8
  • AIS A, B, C
  • ≤ 8 hours
  • NOT have penetrating injury, e.g. gunshot to knife wound
Ended3PHASE1, PHASE2DrugGeneral health
  • Adverse Events (AEs)
  • American Spinal Injury Association Impairment Scale (AIS): International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI)
  • Serum Biomarker
1 year14 February 201714 August 20151
NCT02495545Cerebrospinal Fluid Drainage (CSFD) in Acute Spinal Cord InjurySt. Joseph's Hospital and Medical Center, Phoenix
  • Age 18 - 75 yrs
  • Level C4-C8
  • AIS A, B, C
  • ≤ 24 hours
  • NOT have penetrating injury, e.g. gunshot or knife wound
Ended15NASurgeryGeneral health
  • American Spinal Injury Association Impairment Scale (AIS): International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI)
  • Pain Numeric Rating Scale (NRS)
  • Spinal Cord Independence Measure (SCIM)
180 days01 October 201513 July 20153
NCT02490501Safety and Efficacy of SC0806 (Fibroblast Growth Factor 1 and a Device) in Traumatic Spinal Cord Injury SubjectsBioArctic AB
  • Age 18 - 65 yrs
  • Level T2-T11
  • AIS A
  • 4 months - 10 years
  • have a BMI of less than 35.
  • have a body height of less than 195cm (<6’4 feet).
  • have a body weight of less than 125kg (<275 lbs).
  • be able to undergo and tolerate the MRI scanning.
  • NOT have known hypersensitivity to FGF1 or heparin
Ended10PHASE1, PHASE2Biological/cell basedStanding/walking/mobility
  • Adverse Events (AEs)
  • Motor Evoked Potentials (MEPs)
18 months01 June 201503 July 20151